Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)

Completed · Not applicable

Conditions studied: Cancer of the Cervix, Cervical Neoplasms

In brief

The purpose of this study is to determine the maximum tolerated dose of integrated boost radiation therapy when given with concurrent chemotherapy (cisplatin).

Key facts

Study ID

NCT01627288

Run by

Duke University

People needed

12

Starts

2012-06-04

Expected to finish

2019-11-16

Last updated by the study team

2021-02-08

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy confirmed malignancy of the gynecologic tract
• Involved pelvic or para-aortic lymph nodes
• Treatment plan to include delivery of concurrent chemoradiotherapy.
• Good performance status
• Negative pregnancy test in women of child-bearing potential
• Signed study-specific informed consent
• Lab results within study specific limits

You may not qualify if…

• Prior radiation to the abdomen or pelvis
• A history of Scleroderma or Inflammatory bowel disease
• Contraindication to chemotherapy or radiation

Where it is running

• Radiation Oncology, DUMC — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.